Axsome Therapeutics, Inc.
AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as wā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$211.12
Price+0.23%
$0.49
1Y
Price
Market Cap
$10.864b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-22.7%
EBITDA Margin-23.5%
Net Profit Margin-15.0%
Free Cash Flow Margin-22.7%
EBITDA Margin-23.5%
Net Profit Margin-15.0%
Free Cash Flow MarginRevenue
$776.569m
+21.6%
1y CAGR+43.2%
3y CAGR+142.6%
5y CAGREarnings
-$191.644m
-4.6%
1y CAGR+3.9%
3y CAGR-4.1%
5y CAGREPS
-$3.75
-1.9%
1y CAGR+7.7%
3y CAGR+2.1%
5y CAGRBook Value
$83.304m
$761.447m
Assets$678.143m
Liabilities$219.208m
DebtDebt to Assets
28.8%
-1.2x
Debt to EBITDAFree Cash Flow
-$71.388m
+24.0%
1y CAGR+20.9%
3y CAGR+9.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company